TY  - JOUR
AU  - Oprea-Lager, Daniela-Elena
AU  - MacLennan, Steven
AU  - Bjartell, Anders
AU  - Briganti, Alberto
AU  - Burger, Irene A
AU  - de Jong, Igle
AU  - De Santis, Maria
AU  - Eberlein, Uta
AU  - Emmett, Louise
AU  - Fizazi, Karim
AU  - Gillessen, Silke
AU  - Herrmann, Ken
AU  - Heskamp, Sandra
AU  - Iagaru, Andrei
AU  - Jereczek-Fossa, Barbara Alicja
AU  - Kunikowska, Jolanta
AU  - Lam, Marnix
AU  - Nanni, Cristina
AU  - O'Sullivan, Joe M
AU  - Panebianco, Valeria
AU  - Sala, Evis
AU  - Sathekge, Mike
AU  - Sosnowski, Roman
AU  - Tilki, Derya
AU  - Tombal, Bertrand
AU  - Treglia, Giorgio
AU  - Tunariu, Nina
AU  - Walz, Jochen
AU  - Yakar, Derya
AU  - Dierckx, Rudi
AU  - Sartor, Oliver
AU  - Fanti, Stefano
TI  - European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
JO  - European urology
VL  - 85
IS  - 1
SN  - 0302-2838
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2023-01932
SP  - 49-60
PY  - 2024
N1  - 2024 Jan;85(1):49-60
AB  - In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA radioligand therapy, integration of advanced imaging in nomogram-based decision-making, dosimetry, and development of new theranostic applications.We aimed to critically review developments in molecular hybrid imaging and systemic radioligand therapy, to reach a multidisciplinary consensus on the current state of the art in PCa.The results of a systematic literature search informed a two-round Delphi process with a panel of 28 PCa experts in medical or radiation oncology, urology, radiology, medical physics, and nuclear medicine. The results were discussed and ratified in a consensus meeting.Forty-eight statements were scored on a Likert agreement scale and six as ranking options. Agreement statements were analysed using the RAND appropriateness method. Ranking statements were analysed using weighted summed scores.After two Delphi rounds, there was consensus on 42/48 (87.5
KW  - Molecular hybrid imaging (Other)
KW  - Nuclear medicine (Other)
KW  - Prostate cancer (Other)
KW  - Systemic radioligand therapy (Other)
KW  - Theranostics (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37743194
DO  - DOI:10.1016/j.eururo.2023.09.003
UR  - https://inrepo02.dkfz.de/record/283146
ER  -